

Virginia Ruiz-Esquide

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3668163/publications.pdf>

Version: 2024-02-01

44
papers

767
citations

471061

17
h-index

552369

26
g-index

45
all docs

45
docs citations

45
times ranked

1057
citing authors

#	ARTICLE	IF	CITATIONS
1	Anti-carbamylated proteins antibody repertoire in rheumatoid arthritis: evidence of a new autoantibody linked to interstitial lung disease. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 587-594.	0.5	52
2	Patients with rheumatoid arthritis in clinical remission and ultrasound-defined active synovitis exhibit higher disease activity and increased serum levels of angiogenic biomarkers. <i>Arthritis Research and Therapy</i> , 2014, 16, R5.	1.6	50
3	Serum Calprotectin Versus Acute-Phase Reactants in the Discrimination of Inflammatory Disease Activity in Rheumatoid Arthritis Patients Receiving Tumor Necrosis Factor Inhibitors. <i>Arthritis Care and Research</i> , 2016, 68, 899-906.	1.5	42
4	Anti-citrullinated peptide antibodies in the serum of heavy smokers without rheumatoid arthritis. A differential effect of chronic obstructive pulmonary disease?. <i>Clinical Rheumatology</i> , 2012, 31, 1047-1050.	1.0	39
5	Calprotectin and TNF trough serum levels identify power Doppler ultrasound synovitis in rheumatoid arthritis and psoriatic arthritis patients in remission or with low disease activity. <i>Arthritis Research and Therapy</i> , 2016, 18, 160.	1.6	39
6	Effects of Smoking on Disease Activity and Radiographic Progression in Early Rheumatoid Arthritis. <i>Journal of Rheumatology</i> , 2011, 38, 2536-2539.	1.0	38
7	Sarcoidosis pulmonar inducida por antagonistas del factor de necrosis tumoral en la artritis reumatoide: presentaci3n de un caso y revisi3n de la literatura m3dica. <i>Archivos De Bronconeumologia</i> , 2011, 47, 208-212.	0.4	38
8	Differences in synovial fluid cytokine levels but not in synovial tissue cell infiltrate between anti-citrullinated peptide/protein antibody-positive and -negative rheumatoid arthritis patients. <i>Arthritis Research and Therapy</i> , 2013, 15, R182.	1.6	34
9	Rheumatoid Arthritis: A Clinical Overview of New Diagnostic and Treatment Approaches. <i>Current Topics in Medicinal Chemistry</i> , 2013, 13, 698-704.	1.0	33
10	Immunopathologic characterization of ultrasound-defined synovitis in rheumatoid arthritis patients in clinical remission. <i>Arthritis Research and Therapy</i> , 2016, 18, 74.	1.6	33
11	Palindromic Rheumatism with Positive Anticitrullinated Peptide/Protein Antibodies Is Not Synonymous with Rheumatoid Arthritis. A Longterm Followup Study. <i>Journal of Rheumatology</i> , 2012, 39, 1929-1933.	1.0	31
12	Tabaco y otros factores ambientales en la artritis reumatoide. <i>Reumatolog3a Cl3nica</i> , 2012, 8, 342-350.	0.2	28
13	Calprotectin strongly and independently predicts relapse in rheumatoid arthritis and polyarticular psoriatic arthritis patients treated with tumor necrosis factor inhibitors: a 1-year prospective cohort study. <i>Arthritis Research and Therapy</i> , 2018, 20, 275.	1.6	28
14	Calprotectin more accurately discriminates the disease status of rheumatoid arthritis patients receiving tocilizumab than acute phase reactants. <i>Rheumatology</i> , 2015, 54, kev251.	0.9	26
15	Relapsing polychondritis: a new adverse event secondary to the use of tumour necrosis factor antagonists?. <i>Rheumatology</i> , 2011, 50, 1523-1525.	0.9	23
16	Reducci3n de dosis de terapias biol3gicas en enfermedades reum3ticas: an3lisis descriptivo de 153 pacientes en condiciones de pr3ctica cl3nica. <i>Reumatolog3a Cl3nica</i> , 2014, 10, 10-16.	0.2	22
17	Lung Sarcoidosis Induced by TNF Antagonists in Rheumatoid Arthritis: A Case Presentation and a Literature Review. <i>Archivos De Bronconeumologia</i> , 2011, 47, 208-212.	0.4	19
18	Tobacco and Other Environmental Risk Factors in Rheumatoid Arthritis. <i>Reumatolog3a Cl3nica (English Edition)</i> , 2012, 8, 342-350.	0.2	17

#	ARTICLE	IF	CITATIONS
19	Clinical and sonographic biomarkers of structural damage progression in RA patients in clinical remission: A prospective study with 12 months follow-up. <i>Seminars in Arthritis and Rheumatism</i> , 2017, 47, 303-309.	1.6	17
20	Differing specificities and isotypes of anti-citrullinated peptide/protein antibodies in palindromic rheumatism and rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2017, 19, 141.	1.6	17
21	Is There Subclinical Synovitis in Patients with Palindromic Rheumatism in the Intercritical Period? A Clinical and Ultrasonographic Study According to Anticitrullinated Protein Antibody Status. <i>Journal of Rheumatology</i> , 2014, 41, 1650-1655.	1.0	16
22	Fixed dosing of intravenous tocilizumab in rheumatoid arthritis. Results from a population pharmacokinetic analysis. <i>British Journal of Clinical Pharmacology</i> , 2018, 84, 716-725.	1.1	15
23	Tocilizumab in the treatment of adult rheumatoid arthritis. <i>Immunotherapy</i> , 2018, 10, 447-464.	1.0	15
24	Exposure-response modeling of tocilizumab in rheumatoid arthritis using continuous composite measures and their individual components. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 1710-1718.	1.1	10
25	Differing local and systemic inflammatory burden in polyarticular psoriatic arthritis and rheumatoid arthritis patients on anti-TNF treatment in clinical remission. <i>Clinical and Experimental Rheumatology</i> , 2017, 35, 74-79.	0.4	10
26	Rheumatoid Arthritis Initiating as Palindromic Rheumatism: A Distinct Clinical Phenotype?. <i>Journal of Rheumatology</i> , 2020, 47, 652-657.	1.0	9
27	Anti-carbamylated protein antibody isotype pattern differs between palindromic rheumatism and rheumatoid arthritis. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2020, 12, 1759720X2097813.	1.2	8
28	Biomarkers for treatment change and radiographic progression in patients with rheumatoid arthritis in remission: a 5 year follow-up study. <i>Rheumatology</i> , 2021, 60, 667-674.	0.9	8
29	Reduction of Biological Agent Dose in Rheumatic Diseases: Descriptive Analysis of 153 Patients in Clinical Practice Conditions. <i>Reumatología Clínica (English Edition)</i> , 2014, 10, 10-16.	0.2	7
30	Life-threatening colitis and complete response with ipilimumab in a patient with metastatic BRAF-mutant melanoma and rheumatoid arthritis. <i>ESMO Open</i> , 2016, 1, e000032.	2.0	7
31	Valoración laríngea mediante videolaringoestroboscopia en pacientes con artritis reumatoide. <i>Reumatología Clínica</i> , 2014, 10, 32-36.	0.2	6
32	Laryngeal Assessment by Videolaryngostroboscopy in Patients With Rheumatoid Arthritis. <i>Reumatología Clínica (English Edition)</i> , 2014, 10, 32-36.	0.2	5
33	Evaluation of dose-tapering strategies for intravenous tocilizumab in rheumatoid arthritis patients using model-based pharmacokinetic/pharmacodynamic simulations. <i>European Journal of Clinical Pharmacology</i> , 2020, 76, 1417-1425.	0.8	5
34	Ultrasound findings in palindromic rheumatism. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, e30-e30.	0.5	4
35	High Sensitivity C Reactive Protein in Patients with Rheumatoid Arthritis Treated with Antibodies against IL-6 or Jak Inhibitors: A Clinical and Ultrasonographic Study. <i>Diagnostics</i> , 2022, 12, 182.	1.3	3
36	Proliferative synovitis, an ultrasound pattern associated with ACPA-positive patients and erosive disease in rheumatoid arthritis. <i>Clinical and Experimental Rheumatology</i> , 0, , .	0.4	2

#	ARTICLE	IF	CITATIONS
37	Inflammatory arthropathy of the manubriosternal joint. <i>Rheumatology</i> , 2014, 53, 1731-1731.	0.9	1
38	Comparable long-term outcomes between DAS28-ESR remission criteria and ACR/EULAR definitions in patients with established rheumatoid arthritis. <i>Clinical Rheumatology</i> , 2021, 40, 2665-2672.	1.0	1
39	Proliferative synovitis, an ultrasound pattern associated with ACPA-positive patients and erosive disease in rheumatoid arthritis. <i>Clinical and Experimental Rheumatology</i> , 2021, , .	0.4	1
40	AB0403â€¦PREDICTORS OF PERSISTENCE OF BIOLOGIC DRUG STEP-DOWN STRATEGIES IN INFLAMMATORY ARTHRITIS: A LONGITUDINAL STUDY IN CLINICAL PRACTICE WITH A LONG FOLLOW-UP. , 2019, , .		0
41	FRI0591â€¦RHEUMATIC IMMUNE-RELATED ADVERSE EVENTS ASSOCIATED WITH TREATMENT WITH IMMUNE CHECKPOINT INHIBITORS: A CASE SERIES FROM TWO REFERRAL CENTRES. , 2019, , .		0
42	SAT0107â€¦BIOMARKERS OF CLINICAL RELAPSE AND RADIOLOGICAL PROGRESSION IN PATIENTS WITH RHEUMATOID ARTHRITIS IN REMISSION. OBSERVATIONAL STUDY OF 5 YEARS OF FOLLOW-UP. , 2019, , .		0
43	Effects of smoking on the clinical phenotype and response to treatment in rheumatoid arthritis. <i>International Journal of Clinical Rheumatology</i> , 2013, 8, 221-231.	0.3	0
44	Anti-carbamylated protein antibodies are associated with early abatacept response in rheumatoid arthritis. Comment on: Anti-carbamylated protein antibodies as a clinical response predictor in rheumatoid arthritis patients treated with abatacept. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 1142-1143.	0.4	0